Description: Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Home Page: www.nanexa.com
Virdings Allle 32B
Uppsala,
75450
Sweden
Phone:
46 18 10 03 00
Officers
| Name | Title |
|---|---|
| Mr. David Westberg | Chief Executive Officer |
| Mr. Marten Rooth | Co-Founder, Head of R&D Atomic Layer Deposition and CTO |
| Mr. Anders Johansson | Co-Founder & Head of Intellectual Property |
| Ms. Cecilia Danckwardt-Lilliestrom | Chief Financial Officer |
| Mr. Mikael Asp | Head of QA & Expert Sakkunnig |
| Mr. Joel Hellrup | Head of Pharmaceutical R&D |
| Mr. Otto Skolling M.Sc | Director of Business Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5524 |
| Price-to-Sales TTM: | 0.6564 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |